NeoRx Corporation (Poniard Pharmaceuticals) Announces Participation in Pacific Growth Equities 2006 Life Sciences Growth Confer
June 07 2006 - 9:00AM
PR Newswire (US)
SEATTLE, June 7 /PRNewswire-FirstCall/ -- NeoRx Corporation
(NASDAQ:NERX), which is changing its name to Poniard
Pharmaceuticals, Inc. effective June 16, 2006, today announced that
Jerry McMahon, Ph.D., chairman, president and CEO, will present at
the Pacific Growth Equities 2006 Life Sciences Growth Conference on
Wednesday, June 14, at 8:30 a.m. at the InterContinental Mark
Hopkins Hotel in San Francisco. Dr. McMahon will provide a
corporate update, including a discussion of the clinical
development program for the Company's lead product candidate,
picoplatin, a new generation platinum therapy designed to provide a
differentiated spectrum of activity and an improved safety profile.
Currently, picoplatin is being studied in clinical trials for the
treatment of small cell lung, colorectal and hormone-refractory
prostate cancers. A live audio webcast can be accessed at the
Company's website at http://www.poniard.com/ or
http://www.neorx.com/ on the "Events and Webcasts" page of the
"Investors" section. About NeoRx Corporation and Poniard
Pharmaceuticals On June 16, 2006, NeoRx Corporation will change its
corporate name to Poniard Pharmaceuticals, Inc. A global specialty
pharmaceutical company, Poniard Pharmaceuticals will focus on the
discovery, development and commercialization of innovative oncology
products to impact the lives of people with cancer. Picoplatin, the
Company's lead product candidate, is a new generation platinum
therapy that provides a differentiated spectrum of activity and an
improved safety profile. An intravenous chemotherapeutic agent,
picoplatin is designed to overcome platinum resistance associated
with the treatment of solid tumors. Picoplatin currently is being
studied in clinical trials for the treatment of small cell lung,
colorectal and hormone-refractory prostate cancers. As part of its
strategic goal of building a diverse oncology pipeline, the Company
is collaborating with the Scripps Florida Research Institute on the
discovery of novel, small-molecule, multi-targeted protein kinase
inhibitors. For additional information please visit
http://www.poniard.com/ or http://www.neorx.com/. This release
contains forward-looking statements, including statements regarding
the Company's business model, discovery and development programs
and clinical trial activities. The Company's actual results may
differ materially from those indicated in these forward looking
statements based on a number of factors, including anticipated
operating losses, uncertainties associated with research,
development, clinical trials and related regulatory approvals,
future capital needs and uncertainty of additional financing,
competition, uncertainties associated with intellectual property,
dependence on third-party manufacturers, suppliers and
collaborators, lack of sales and marketing experience, loss of key
personnel, uncertainties associated with market acceptance,
technology change and government regulation, and the other risks
and uncertainties described in the Company's current and periodic
reports filed with the Securities and Exchange Commission,
including the Company's Annual Report on Form 10-K for the year
ended December 31, 2005 and its Quarterly Report on Form 10-Q for
the quarter ended March 31, 2006. Readers are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date of this release. The Company undertakes
no obligation to update any forward-looking statement to reflect
new information, events or circumstances after the date of this
release or to reflect the occurrence of unanticipated events.
DATASOURCE: NeoRx and Poniard Pharmaceuticals CONTACT: Julie
Rathbun, Corporate Communications of Poniard Pharmaceuticals c/o
NeoRx Corporation, +1-206-286-2517, or Web site:
http://www.neorx.com/
Copyright
Neorx (NASDAQ:NERX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Neorx (NASDAQ:NERX)
Historical Stock Chart
From Dec 2023 to Dec 2024